Nature Medicine

doi: 10.1038/nm.4234pmid: 27824816

The US Food and Drug Administration approved a muscular-dystrophy drug against the scientific advice of its own staff and advisors. Despite leadership's attempts to downplay the controversy, doubts now surround standards for accelerated approval.

Keener, Amanda B

doi: 10.1038/nm1116-1194pmid: 27824819

Chakradhar, Shraddha

doi: 10.1038/nm1116-1197pmid: 27824813

Willyard, Cassandra

doi: 10.1038/nm1116-1200pmid: 27824821

doi: 10.1038/nm1116-1202pmid: 27824822

In the October 2016 issue, the piece “Reservoirs of resistance: To understand why antibiotics fail, geneticists chase the 'resistome'” (Nat. Med. 22, 1069–1071, 2016) neglected to include the full name and affiliation of Evan Jones, one of the sources quoted in the piece. Evan Jones serves as the CEO of OpGen.

Zou, Wei; Rohatgi, Nidhi; Chen, Timothy Hung-Po; Schilling, Joel; Abu-Amer, Yousef; Teitelbaum, Steven L

doi: 10.1038/nm.4208pmid: 27824823

Evans, Ronald M; Wan, Yihong

doi: 10.1038/nm.4207pmid: 27824815

Hammond, Timothy R; Stevens, Beth

doi: 10.1038/nm.4226pmid: 27824814

A new study presents a protocol to differentiate human induced pluripotent stem cells (iPSCs) into microglia that closely resemble their in vivo counterparts. These cells offer an exciting new tool for learning more about the role of microglia in disease.

Troy, Carol M; Shelanski, Michael L

doi: 10.1038/nm.4227pmid: 27824824

Misfolded and hyperphosphorylated forms of the microtubule-associated protein tau are thought to be responsible for some degree of neurodegeneration. The demonstration of a novel toxic cleavage of tau by caspase-2 opens up new therapeutic avenues.

Emblem, Kyrre E; Jain, Rakesh K

doi: 10.1038/nm.4228pmid: 27824818

A recent study confirms an association between vessel co-option and resistance to bevacizumab, an anti-vascular endothelial growth factor-A (VEGFA) antibody, in patients with liver metastases. The authors suggest a combined therapeutic strategy that reduces co-option in mice.